AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

AbbVie (ABBV) and Genmab (GMAB) reported positive Phase 3 trial results for epcoritamab combined with R-CHOP in diffuse large B-cell lymphoma (DLBCL). The trial showed a 51% reduction in disease progression or death risk. Both companies plan to engage regulators based on these findings.

Original reporting
Published Oct 5, 2026, 6:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV · $GMAB
Relevance
9/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The data represent a pivotal efficacy signal that could lead to regulatory submissions and commercial rollout, impacting both AbbVie and Genmab valuations.

02

Market read

First report of significant Phase 3 results for a lymphoma therapy; likely to move both stocks and influence the broader oncology biotech space.

03

What to watch

Potential competition from other bispecifics and the need for FDA filing strategy.

Relevance 9/10Novelty 9/10Timing: today

Background

The article is a PR release announcing first interim analysis of a Phase 3 trial for epcoritamab combined with R-CHOP in newly diagnosed DLBCL patients.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase 3 EPCORE DLBCL-2 trial results showing a 51% reduction in risk of progression versus R-CHOP alone.

Expected impact

upward pressure as investors price in potential revenue from epcoritamab in frontline DLBCL.

Evidence & confidence

First disclosure of statistically significant PFS improvement; large oncology franchise and U.S. listing make the news material.

$GMABBullishHigh confidence
Context

Genmab reported the same Phase 3 EPCORE DLBCL-2 topline results, confirming a 51% risk reduction in progression.

Expected impact

upward pressure as market anticipates licensing revenue and potential FDA filing.

Evidence & confidence

First report of pivotal trial success for a product co-developed with AbbVie; significant for Genmab's pipeline.

Market effects

Strengthens the oncology/biotech sector outlook, especially for bispecific antibodies.

Positive for U.S. and European biotech markets where both companies are listed.

Adds confidence to global lymphoma treatment pipelines, may influence peer valuations.

Counterpoint

If regulatory scrutiny delays approval, the initial hype could fade and cause a pullback.

Key entities

  • AbbVie

    U.S.-based biopharma partner developing epcoritamab.

  • Genmab A/S

    Danish biotech co-developer of epcoritamab.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.